Policies to enhance the efficiency of prescribing in the Spanish Catalan region: Impact and future direction

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 6, 2009, Pages 569-581

  Coma, Anna ^b   Zara, Corinne ^b   Godman, Brian ^a,c,d   Agustí, Antònia ^e   Diogène, Eduardo ^e   Wettermark, Björn ^d,f   Haycox, Alan ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b C Agy Hlth Technol Assess Res   (Spain)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

Drug costs and expenditure; Drug utilization; Generics; Pharmaceuticals; Reforms; Spain

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ATORVASTATIN; CANDESARTAN; CITALOPRAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESCITALOPRAM; ESOMEPRAZOLE; EZETIMIBE; FLUOXETINE; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; LISINOPRIL; LOSARTAN; MEVINOLIN; NORADRENALIN UPTAKE INHIBITOR; OMEPRAZOLE; PANTOPRAZOLE; PAROXETINE; PRAVASTATIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RAMIPRIL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIMVASTATIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AMBULATORY CARE; ARTICLE; COST CONTROL; DRUG COST; DRUG UTILIZATION; EUROPE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; OBSERVATIONAL STUDY; PRESCRIPTION; REIMBURSEMENT; SPAIN;

AMBULATORY CARE; DRUG COSTS; DRUGS, GENERIC; HEALTH POLICY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; REIMBURSEMENT MECHANISMS; SPAIN;

EID: 73549092130     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.58     Document Type: Article

References (68)

1. Antoňanzas F, Oliba J, Pinillos M, Juàrez C. Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur. J. Health Econ. 8, 297-300 (2007).
2. Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoeconomics Outcomes Res. 9, 65-83 (2009).
3. Puig-Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67, 149-165 (2004).
4. Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth 14(2), 18-22 (2008).
5. Seeley E. Maximising the benefits from generic competition. Euro. Observer. 10(2), 9-11 (2008).
6. Kanavos P. Generic policies: rhetoric vs. reality. Euro. Observer. 10(2), 1-6 (2008).
7. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91-98 (2008).
8. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking -an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 1-11 (2009).
9. Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res. 9(5), 475-484 (2009).
10. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
11. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J. 28, 88-136 (2007).
12. Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947-2953 (2006).
13. Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 167, 950-955 (2007).
14. Choudry M, Soran H, Ziglam H. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM 101, 445-448 (2008).
15. Leaonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047-2056 (2007).
16. Hawkey C. Drugs that cause and heal peptic ulcer disease. Basic Clin. Pharm. Toxicol. 105(Suppl. 1), 17 (2009).
17. Walley T, Folino-Gallo P, Schwabe U, van Ganse E; on behalf of the EuroMedStat Group. Variations and increase use of statins across Europe: data from administrative databases. BMJ 328, 385-386 (2004).
18. Barbui C, Hotopf M, Freemantle N et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst. Rev. (4), CD002791 (2000).
19. Thompson C, Peveler RC, Stephenson D, McKendrick J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am. J Psychiatry 157(3), 338-343 (2000).
20. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52(12), 1166-1174 (2005).
21. Agüera-Ortiz L, Ramos Garcia I. Effectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder. Actas Esp. Psiquiatr. 34(3), 153-161 (2006).
22. Yu-Isenberg KS, Fontes CL, Wan GJ et al. Acute and continuation treatment adequacy with venlafaxine extended release compared with fluoxetine. Pharmacotherapy 24(1), 33-40 (2004).
23. Baldomero EB, Ubago JG, Cercós CL et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress. Anxiety 22(2), 68-76 (2005).
24. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms m Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27(5), 435-438 (2009).
25. Godman B, Vlahovic-Palcevski V, Laius O et al. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Basic Clin. Pharm. Toxicol. 105(Suppl. 1), 37 (2009).
26. Godman B, Wettermark B, Vlahovic-Palcevski V et al. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. Basic Clin. Pharm. Toxicol. 105(Suppl. 1), 35 (2009).
27. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 336, 2-3 (2008).
28. Björnsson E, Abrahssom H, Simrén M et al. Discontinuation of proton pump inhibitors m patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol. Ther. 24, 945-954 (2006).
29. Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candersartan in a primary care setting. Int. J. Clin. Pract. 61(1), 15-23 (2007).
30. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484 (2008).
31. Sakshaug S, Furu K, Karlstead O et al. Switching statins in Norway after new reimbursement policy -a nationwide prescription study. Br. J. Clin. Pharm. 64, 476-481 (2007).
32. Kastelein J, Akdim F, Stroes E et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N. Engl. J. Med. 358(14), 1431-1443 (2008).
33. Brown GB, Taylor A. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N. Engl. J. Med. 358(14), 1504-1507 (2008).
34. Cipriani A, Santilli C, Furukawa TA et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst. Rev. 2, CD006532 (2009).
35. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med. 148, 16-29 (2008).
36. Frisk P, Mellgren TO, Hedberg N et al. Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol. 64, 1223-1229 (2008).
37. Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract. 62, 76-87 (2008).
38. Wettermark B, Godman B, Neovius M, Hedberg N et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy DOI:10.1016/j.healthpol.2009. 09.014' (2009) (Epub ahead of print).
39. Gandía-Moya MC. Do we primary care doctors improve our prescription of generic medicines after the intervention of the area pharmacist. Aten. Primaria 37(7), 386-391 (2006).
40. Tresserras R, Brugulat P. Catalonia: improved intelligence and accountability? In: Health Targets in Europe: Learning from Experiences. Wismar M, McKee M, Ernst K et al. (Eds). European Observatory (2008) www.euro.who.int/Document/E91867.pdf (Accessed 15 December 2008)
41. Durán A, Lara JL, van Waveren M. Spain: health system review. Health Syst. Trans. 8(4), 1-208 (2006). www.euro.who.int/Document/E89491. pdf (Accessed 15 December 2008)
42. Durán A, Lara JJ, van Waveren M. Spain: Health Systems in Transition (HiT) Summary. European Observatory 2006 www.euro.who.int/Document/ E89491sum.pdf (Accessed 15 December 2008)
43. OECD data on pharmaceutical expenditure www.oecd.org/document/16/0,3343, en-2649-34631-2085200-1-1-1-1,00.html (Accessed 15 September 2009)
44. Simoens S, De Coster S. Sustaining Generic Markets in Europe. Leuven: Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics 2006 www.egagenerics.com/doc/simoens-report-2006-2004.pdf (Accessed 15 December 08)
45. Primary Healthcare Centre guidelines in Catalonia (In Spanish) www.gencat.cat/ics/professionals/guies/index.htm (Accessed 1 December 2008)
46. Drug information bulletins. (In Spanish) www.gencat.net/salut/depsan/ units/sanitat/html/ca/publicacions/spbit.htm (Accessed 1 December 2008)
47. 61 quality-of-care indicators and 21 quality-of-prescription indicators (In Spanish) www.gencat.cat/ics/professionals/pdf/eqpf-2008.pdf (Accessed 1 December 2008)
48. Ministerio de Sanidad y Consumo. Ley 16/2003 de 28 de mayo, de cohesion y calidad del sistema Nacional de Salud. BOE núm 128 www.msps.es/ organizacion/sns/planCalidadSNS/pdf/transparencia/LEY-COHESION-Y-CALIDAD.pdf (Accessed 18 October 2009)
49. WHO. Guidelines for ATC classification and DDD assignment 2009. Oslo: WHO Collaborating Centre for Drug Statistics Methodology www.whocc.no (Accessed 15 January 2009)
50. Management of hypercholesterolemia (In Spanish) www.gencat.cat/ics/ professionals/guies/docs/guia-hipercolesterolemia.pdf (Accessed 1 December 2008)
51. Eriksson G, Lundin D. The review of medicines for treating lipid disorders: a summary. TLV Sweden 2009 www.tlv.se/Upload/Genomgangen/summary- lipids.pdf (Accessed 30 March 2009)
52. Management of hypertension (In Spanish) www.gencat.cat/ics/professionals/ guies/docs/guia-hipertensio-completa.pdf (Accessed 1 December 2008)
53. Management of cardiac insufficiency (In Spanish) www.gencat.cat/ics/ professionals/guies/docs/guia-insuficiencia-cardiaca.pdf (Accessed 1 December 2008)
54. Carter S, Taylor D, Levenson R. A question of choice - compliance in medicine taking; a preliminary review (2005) www.npci.org.uk/adherence-to- medicines/atm/intro/resources/library-qoc-compliance.pdf (Accessed 10 May 2009)
55. WHO. Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330) www.who.int/medicines/areas/quality-safety/safety-efficacy/ Drug%20utilization%20research.pdf (Accessed 30 April 2009)
56. Institute of Statistics - Inhabitants of Catalonia www10.gencat.net/ catsalut/cat/asseg-quies.htm (Accessed 30 April 2009)
57. RD 2402/2004 de 30 de diciembre por el que se desarrolla el articulo 104 de la ley 25/1990, de 20 de diciembre, del Medicamento, para las revisiones coyunturales de precios de especialidades farmacéuticas y se adoptan medidas adicionales para la contención del gasto farmacéutico. BOE num 315. www.boe.es/boe/dias/2004/12/31/pdfs/A42819-42905.pdf (Accessed 18 October 2009)
58. Wessling A, Ramsberg J. Review of antidepressants: a summary. Solna: Dental and Pharmaceutical Benefits Agency www.tlv.se/Upload/Genomgangen/review- antidepressants-summary.pdf (Accessed 5 January 2009)
59. Escitalopram Scottish Medicines Consortium November 2002 www.scottishmedicines.org.uk/smc/files/Escitalopram-for-depressionAdvice(8-11- 02).pdf (Accessed 5 January 2009)
60. Escitalopram Oxalare. CDEC Final recommendation and reconsideration. Jan 2007 www.cadth.ca/media/cdr/complete/cdr-complete-Cipralex-Resubmission-Jan-24- 2007.pdf (Accessed 5 January 2009)
61. Hedberg N, Jacob J. A review of medicines for lowering blood pressure - a summary. Solna: Pharmaceuticals Benefits Board, 2008 [online] www.tlv.se/Upload/Genomgangen/ summary-blood-pressure.pdf (Accessed 17 December 2008)
62. Office of Fair Trading (UK). The Pharmaceutical Price Regulation System - An OFT study. February 2007. Annexe M: current price inefficiencies and potential benefits of value-based pricing London: OFT 2007 www.oft.gov.uk/ shared-oft/reports/comp-policy/oft885m.pdf (Accessed 5 December 2008)
63. Beishon J, McBride T, Scharaschkin S et al; National Audit Office. Prescribing costs in primary care. 14 May 2007 www.nao.ork.uk (Accessed 21 May 2008)
64. Management of dyspepsia (In Spanish) www.gencat.cat/ics/professionals/ guies/dispepsia/docs/guia-dispepsia.pdf (Accessed 1 December 2008)
65. Catsalut Regió Sanitària Barcelona. Butlletí E-farma RSB (In Spanish) www10.gencat.net/catsalut/rsb/farmacia/efarma/index.htm (Accessed 18 May 2009)
66. Fundació Institut Català. Butlletí Groc. www.icf.uab.es/informacion/boletines/bg/asp/bg-c.asp (Accessed 18 May 2009)
67. Generalitat de Catalunta. Butlletí de Farmacovigilàcia de Catalunya. www.gencat.cat/salut/depsalut/html/ca/dir1847/butfarma.htm (Accessed 18 May 2009)
68. Introduction to e-learning courses on primary care problems (In Spanish) www.gencat.net/salut/ies/Du11/html/ca/dir1523/doc10745.html (Accessed 1 December 2008)